6 Literaturverzeichnis

[1] MÜLLER-JAHNKE, W.-D.; FRIEDRICH, C.: Geschichte der Arzneimitteltherapie, Deutscher Apothekerverlag Stuttgart, 231-235, (1996)

[2] REYA, T.; MORRISON, S. J.; CLARKE, M. F.; WEISSMANN, I. L.: Stem cells, cancer, and cancer stem cells, Nature, **414**, 105-111, (2001)

[3] RUBIO, D.; GARCIA-CASTRO, J.; MARTIN, M. C.; DE LA FUENTE, R.; CIGUDOSA, J.; LLOYD, A. C.; BERNAD, A.: Spontaneous human adult stem cell transformation, Cancer Res., **8**, 3035-3039, (2005)

[4] COGHLAN, A.: Old stem cells can turn cancerous, New Sci., 2005.

[5] PARDAL, R.; CLARKE, M. F.; MORRISON, S. J.: Applying the principles of stem-cell biology to cancer, Nat. Rev. Cancer, **3**, 895-902, (2003)

[6] PERKEL, J. M.: Colon cancer stem cells identified, The Scientist, (2006)

[7] FEURING-BUSKE, M.: Grundlagenforschung, Arbeitsgruppe: Stammzellbiologie (AG Feurig-Buske), Klinikum Uni-München

[8] www.krebshilfe.de, Deutsche Krebshilfe

[9] GESELLSCHAFT DER EPIDEMIOLOGISCHEN KREBSREGISTER IN DEUTSCHLAND E. V. IN ZUSAMMENARBEIT MIT DEM ROBERT KOCH-INSTITUT: Krebs in Deutschland Häufigkeiten und Trends, Saarbrücken, **5**, (2006)

[10] KOOLMAN, J.; RÖHM, K.-H.: Taschenatlas der Biochemie, **2. Auflage**, Georg Thieme Verlag Stuttgart•New York, 376-379, (1998)

[11] MUTSCHLER, E.; GEISSLINGER, G.; KROEMER, H. K.; SCHÄFER-KORTING, M.: Arzneimittelwirkungen, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, **8. Auflage**, 873-884, (2001)

[12] THEWS, G.; MUTSCHLER, E; VAUPEL, P.: Anatomie, Physiologie, Pathophysiologie des Menschen, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, **6. Auflage**, 117-120, (1999)

[13] LÜLLMANN, H.; MOHR, K.: Taschenatlas der Pharmakologie und Toxikologie, Georg Thieme Verlag: Stuttgart•New York, **4. Auflage**, 304-307, (1999)

[14] SEGOTA, E.; BUKOWSKI, R. M.: The promise of targeted therapy: cancer drugs become more specific, Cleveland Clinic Journal of Medicine, **71**, 551-560, (2004)

[15] LEMMER, B.; BRUNE, K.: Pharmakotherapie Klinische Pharmakologie, Springer Medizin Verlag Heidelberg, **13. Auflage**, 164-175, (2007)

[16] N.N.: Trastuzumab, Dtsch. Apoth. Ztg., Beil.: Neue Arzneimittel, **1**, (2001)

[17] N.N.: Ibritumomab-Tiuxetan, Dtsch. Apoth. Ztg., Beil.: Neue Arzneimittel, **1**, (2004)

[18] N.N.: Imatinib, Dtsch. Apoth. Ztg., Beil.: Neue Arzneimittel, **1**, (2002)

[19] N.N.: Bortezomib, Dtsch. Apoth. Ztg., Beil.: Neue Arzneimittel, **1**, (2004)

[20] WELLS, A.: EGF receptor, Int. J. Biochem. Cell Biol., **31**, 637-643, (1999)

[21] COHEN, S.: Isolation of a mouse subaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal, J. Biol. Chem., **237**, 1555-1562, (1962)

[22] KHOLODENKO, B. N.; DEMIN, O. V.; MOEHREN, G.; HOEK, J. B.: Quantification of Short Term Signaling by the Epidermal Growth Factor Receptor, J. Biol. Chem., **274**, 30169-30181, (1999)

[23] STORTELERS, C.; VAN DER WONING, S. P.; JACOBS-OOMEN, S.; WINGENS, M.; VAN ZOELEN, E. J.: Selective formation of ErbB-2/ErbB-3 heterodimers depends on the ErbB-3 affinity of Epidermal Growth Factor-like ligands, J. Biol. Chem., **278**, 12055-12063, (2003)

[24] CHO, H.-S.; MASON, K.; RAMYAR, K. X.; STANLEY, A. M.; GABELLI, S. B.; DENNEY, D. W., JR.; LEAHY, D. J.: Structure of the extracellular region of HER2 alone and in complex with the herceptin fab, Nature, **421**, 756-760, (2003)

[25] NAVOLANIC, P. M.; STEELMAN, L. S.; MCCUBREY, J. A.: EGFR family signaling and its association with breast cancer development and resistence to chemotherapy (Review), Int. J. Onc., **22**, 237-252, (2003)

[26] BAZLEY, L. A.; GULLICK, W. J.: The epidermal growth factor receptor family, Endocr. Rel. Cancer, **12**, 17-27, (2005)

[27] JOHNS, T. G.; ADAMS, T. E.; COCHRAN, J. R.; HALL, N. E.; HOYNE, P. A.; OLSEN, M. J.; KIM, Y.-S.; ROTHACKER, J.; NICE, E. C.; WALKER, F.; RITTER, G.; JUNGBLUTH, A. A.; OLD, L. J.; WARD, C. W.; BURGESS, A. W.; WITTRUP, K. D.; SCOTT, A. M.: Identification of the epitope for the Epidermal Growth Factor Receptor-specific monoclonal antibody 806 reveals that It preferentially recognizes an untethered form of the receptor. J. Biol. Chem., **279**, 30375-30384, (2004)

[28] WEAVER, C. H.; MAXON, J.: Targeting epidermal growth factor receptor pathways, Current Topics In Oncology, (2002)

[29] PEDERSON, M. W.; POULSON, H. S.: Epidermal growth factor receptor in cancer therapy, Science& Medicine, **8**, 206, (2000)

[30] WENDONG, L.; MAYOTTE, J. E.; LEVITT, M. L.: Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells, Anticancer Res., **19**, 221-228, (1999)

[31] MÜLLER, G.; KLEBL, B.: Small molecule kinase inhibitors: a chemogenomics opportunity, Mainzer Forum Medizinische Chemie (Veranst.), Kurzfassungen der Vorträge im Rahmen des Mainzer Forums Medizinische Chemie, 6-9, (2003)

[32] SCHÜTTE, J.; BAUER, S.: Ansätze zur Therapie mit STI571 (Imatinib) bei soliden Tumoren, innovartis, **3**, 31-37, (2001)

[33] ROBINSON, D. R.; WU, Y.-M.; LIN, S.-F.: The protein tyrosine kinase family of the human genome, Oncogene, **19**, 5548-5557, (2000)

[34] CLARK, J.; COOLS, J.; GILLILAND, D. G.: EGFR inhibition in Non-Small Cell Lung Cancer: resistence, once again, rears ist ugly head, PLOS Med, **2**, (2005)

[35] SCHLESSINGER, J.: Cell signaling by receptor tyrosine kinase, Cell, **103**, 211-225, (2000)

[36] SCHOEBERL, B.; RODRIGUEZ, J. S.: EGF-induced MAP Kinase Cascade in HeLa cells, Max-Planck-Gesellschaft, Max-Planck-Institut für Dynamik komplexer technischer Systeme, (2005)

[37] KAMATH, S.; BUOLAMWINI, J. K.: Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development, Med. Res. Rev., **26**, 569-594, (2006)

[38] HILGER, R. A.; SCHEULEN, M. E.; STRUMBERG, D.: The Ras-Raf-MEK-ERK pathway in the treatment of cancer, Onkologie, **25**, 511-518, (2002)

[39] ALBERTS, B.; BRAY, D.; LEWIS, J.; RAFF, M.; ROBERTS, K.; WATSON, J. D.: Molecular Biology of the cell, Garland Publishing·New York, **3. Auflage**, 745-771, (1994)

[40] YEH, T. C.; PELLEGRINI, S.: The janus kinase family of protein tyrosine kinases and their role in signaling, Cell. Mol. Life. Sci., **55**, 1523-1534, (1999)

[41] RADTKE, S.: Die Regulation der Expression des humanen Oncostatin M Rezeptors durch Januskinasen, Dissertation, Rheinisch-Westfälische Technische Hochschule Aachen, (2003)

[42] N.N.: Neue Therapieansätze des nicht kleinzelligen Lungenkarzinoms, (www.roche.de)

[43] MEDINGER, M.; SOLTAU, J.; UNGER, C.; DREVS, J.: Rezeptor-Tyrosinkinasen Angriffspunkte für neue Tumortherapien, Med. Monatsschr. Pharm., **27**, 50-58, (2004)

[44] KÄMMERER, W.: Trastuzumab verbessert Überlebenschance, Pharm. Ztg., **152**, 34, (2007)

[45] MÜLLER, S.: Merck KGaA erhält Zulassung von der EMEA für Erbitux bei Kopf- und Halskrebs, Merck KGaA, Investor Relations information, Pressemitteilung, (2006).

[46] Al-Obeidi, F. A.; Lam, K. S.: Development of inhibitors for protein tyrosine kinases, Oncogene, **19**, 5690-5701, (2000)

[47] N.N.: Sunitinib punktet bei metastasiertem Brustkrebs, Ärzte Zeitung, (2007)

[48] SCHMIDINGER, M.; LOIDL, W.: Sunitinib, Arzneimittelprofil, Medizin Medien Austria, 3-**14**, (2007)

[49] JUNKER, A.: Sunitinib jetzt auch für die Erstlinientherapie zugelassen, Dtsch. Ärztebl., **104**, A-365, (2007)

[50] GREIL, R.; MICKSCHE, M.: Sorafenib, Arzneimittelprofil, Medizin Medien Austria, 3-12, (2006)

[51] STRUMBERG, D.; MARTINI, B.: Sorafenib – Neue Therapieoptionen in der Onkologie. Arzneimitteltherapie, **25**, 2-5, (2007)

[52] MAMOT, C.; ROCHLITZ, C. F.: Iressa™, Tarceva™ und Erbitux™ - Medikamente einer neuen Generation, Nova-Schweiz Med. Forum, 475-479, (2005)

[53] N.N.: Medienmitteilung, Neues Medikament zur Behandlung des Lungenkrebses. Astra Zeneca, (2004)

[54] N.N.: FDA „friert" Zulassung von Gefitinib ein, Dtsch. Ärztebl., **25**, (2005)

[55] N.N.: New labeling and distribution program for Gefitinib (Iressa), FDA, (2005)

[56] GRÄFE, K. A.: Erlotinib schenkt Lebenszeit, Pharm. Ztg., **150**, (2005)

[57] N.N.: Erlotinib (Tarceva) erhält EU-Zulassung, Journal Onkologie, (2005)

[58] SHEPHERD, F. A.; PEREIRA, J. R.; CIULEANU, T.; TAN, E. H.; HIRSH, V.; THONGPRASERT, S.; CAMPOS, D.; MAOLEEKOONPIROJ, S.; SMYLIE, M.; MARTINS, R.; VAN KOOTEN, M.; DEDIU, M.; FINDLAY, B.; TU, D.; JOHNSTON, D.; BEZJAK, A.; CLARK, G.; SANTABARBARA, P.; SEYMOUR, L.: Erlotinib in Previously Treated Non-Small-Cell Lung Cancer, The New Engl. J. Med., **353**, 123-132, (2005)

[59] N.N.: FDA approves tykerb (lapatinib tablets) for advanced metastatic breast cancer patients, U.S. Food and Drug Administration, (2007)

[60] BECKER, C.: Lapatinib als neuer Hoffnungsträger, PZ online (2007)

[61] BAYAZIT, V.; KHAN, K.: Anticancerogen activities of biological and chemical agents on lung carinoma, breast adenocarcinoma and leukemia in rabbits, J. Chem. Soc. Pakistan, **4**, 314-422, (2005)

[62] OGATA, R.; KITAMURA, K.; ITO, Y.; NAKANO, H.: Inhibitory effects of genistein on ATP-sensitive K+ channels in rabbit portal vein smooth muscle, Brit. J. Pharm., **122**, 1395-1404, (1997)

[63] YANG, E. B.; WEI, L.; ZHANG, K.; CHEN, Y. Z.; CHEN, W. N.: Tannic acid, a potent inhibitor of epidermal growth factor receptor tyroine kinase, J. Biochem., **3**, 495-502, (2006)

[64] FRITZ, W. A.; WANG, J.; ELTOUM, I. E.; LAMARTINIERE, C. A.: Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate, Mol. Cell. Endocrinol., **1**, 89-99, (2002)

[65] ATLURU, S.; ATLURU, D.: Evidence that genistein, a protein-tyrosine kinase inhibitor, inhibits CD28 monoclonal-antibody-stimulated human T cell proliferation, Transplantation, **51**, 448-450, (1991)

[66] AKIYAMA, T.; ISHIDA, J.; NAKAGAWA, S.; OGAWARA, H.; WATANABE, S.; ITOH, N.; SHIBUYA, M.; FUKAMI, Y.: Genistein, a specific inhibitor of tyrosine-specific protein kinases, J. Biol. Chem., **262**, 5592-5595, (1987)

[67] TRAXLER, P.; GREEN, J.; METT, H.; SÉQUIN, U.; FURET, P.: Use a pharmacophore Model for the design of EGFR Tyrosine Kinase Inhibitors: Isoflavones and 3-Phenyl-4-(1H)-quinolones, J. Med. Chem., **42**, 1018-1026, (1999)

[68] TRAXLER, P.: Tyrosin kinase inhibitors in cancer treatment (Part II), Exp. Op. Ther. Pat., **8**, 1599-1625, (1998)

[69] HOU, T.; ZHU, L.; CHEN,L.; XU, X.: Mapping the Binding Site of a Large Set of Quinazoline Type EGFR-Inhibitors Using Molecular Field Analyses and Molecular Docking Studies, J. Chem. Inf. Comput. Sci., **43**, 273-287, (2003)

[70] DANNEEL, R.: Die Giftwirkung des Rotenons und seiner Derivate auf Fische, Naunyn-Schmiedeberg's Archives of Pharmacology, **170**, 59-71, (1933)

[71] TAMM, L.; SPEISER, B.; WYSS, E.; NIGGLI, U.: Einsatz von Rotenon im biologischen Landbau: Positionspapier FiBL, Forschungsinstitut für Biologischen Landbau, (2000)

[72] SCHÖLLER, M.; PROZELL, S.: Richtlinien der Verbände des ökologischen Landbaus zum Vorratsschutz, Gesunde Pflanzen, **57**, 1-5, (2005)

[73] ERNSTER, L.; DALLNER, G.; AZZONE, G. F.: Differential Effects of Rotenone and Amytal on Mitochondrial Electron and Energy Transfer, J. Biol. Chem., **238**, 1124-1131, (1963)

[74] BURGER, A.; WACHTER, H.: Hunnius Pharmazeutisches Wörterbuch, Walter de Gruyter Berlin•New York, **9. Auflage**, 1318, (2004)

[75] WITZEL, S.: Synthesen und Pharmakologie neuer Chromanol-, Isoflavon- und Indolderivate, Dissertation, Freie Universität Berlin, (1999)

[76] BIBERGER, C.; VON ANGERER, E.: 1-benzyl-2-phenylindole- and 1,2-diphenylindole-based antiestrogens. Estimation of agonist and antagonist activities in transfection assays, J. Steroid Biochem. Molec. Biol., **64**, 277-285, (1998)

[77] BURDALL, S. E.; HANBY, A. M.: LANDSDOWN, M. R. J.; SPEIRS, V.: Breast cancer cell lines: friend or foe?, Breast Cancer Res., **5**, 89-95, (2003)

[78] ALBUSCHAT, R.: Neue EGFR-Tyrosinkinase-Inhibitoren mit Salicyloyl- oder Chianzolin-Teilstrukturen, Dissertation, Freie Universität Berlin, (2003)

[79] TAPPMEYER, S.: Versuche zur Herstellung selektiver Estrogenrezeptor-Modulatoren mit Isoflavon-, 3-Salicyloylindol- und 3-Phenyl-4-chinazolinonteilstrukturen, Dissertation, Freie Universität Berlin, (2004)

[80] FAULL, A. W.; KETTLE, J.: Anti-inflammatory indole derivatives, United States Patent, No.: 6569888, (2003)

[81] BOES, M.: Indole derivatives, United States Patent, No.: 5494928, (1996)

[82] LÜTH, A.: Synthese substituierter 4-(Indol-3-yl)Chinazoline – eine neue Klasse von EGFR-Tyrosinkinase-Inhibitoren, Dissertation, Freie Universität Berlin, (2006)

[83] HADFIELD, J. A.; GAUKROGER, K.; HIRST, N.; WESTON, A. P.; LAWRENCE, N. J.; MCGOWN, A. T.: Synthesis and evaluation of double bond substituted combretastatins, Eur. J. Med. Chem., **40**, 529-541, (2005)

[84] LIOU, J.-P., CHANG, Y.-L., KUO, F.-M.; CHANG, C.-W.; TSENG, H.-Y.; WANG, C.-C.; YANG, Y.-N.; CHANG, J.-Y.; LEE, S.-J.; HSIEH, H.-P.: Concise synthesis and structure-activity relationships of Combretastatin A-4 analogues, 1-Aroylindoles and 3-Aroylindoles, as novel classes of potent antitubulin agents, J. Med. Chem., **47**, 4247-4257, (2004)

[85] PETTIT, G. R.; SINGH, S. B.; HAMEL, E.; LIN, C. M.; ALBERTS, D. S.; GARCIA-KENDAL, D., Isolation and structure og the strong cell growth and tubulin inhibitor combretastatin A-4, Cellular and Molecular Life Sciences, **45**, 209-211, (1989)

[86] BARTSCH, V.: Wirkmechanismus der Taxane, Pharm. Unserer Zeit, **34**, 104-108, (2005)

[87] LIN, C. M.; HO, H.; PETTIT, G. R.; HAMEL, E.: Antimitotic Natural Products Combretastatin A-4 and Combretastatin A-2: Studies on the Mechanism of Their Inhibition of the Binding of Colchicine to Tubulin, Biochemistry, **28**, 6984-6991, (1989)

[88] ONODA, T.; ISSHI, K; TAKEUCHI, T; TATSUTA, K; UMEZAWA, K.: Inhibition of tyrosine kinase and epidermal growth factor receptor internalization by lavendustin A methyl ester in cultured A431 cells, Drugs Under Experimental and Clinical Research, **16**, 249-253, (1990)

[89] NUSSBAUMER, P.; WINISKI, A. P.; CAMMISULI, S.; HIESTAND, D.; WECKBECKER, G.; STÜTZ, A.: Novel Antiproliferative Agents Derived from Lavendustin A, J. Med. Chem., **37**, 4079-4084, (1994)

[90] SU, C. G.; WEN, X.; BAILEY, S. T.; JIANG, W.; RANGWALA, S. M.; KEILBAUGH, S. A.; FLANIGAN, A.; MURTHY, S.; LAZAR, M. A.; WU, G. D.: A novel therapy for colitis utilizing PPAR-γ ligand to inhibit the epithelial inflammatory response, J. Clin. Invest., **104**, 383-389, (1999)

[91] AKTORIES, K. F., U.; HOFMANN, F. B.; STARKE, K.: Allgemeine und spezielle Pharmakologie und Toxikologie, Elsevier Urban & Fischer München•Jena, **9. Auflage**, 571-573, (2005)

[92] GLAS, J.; MARKUS, C.; TÖRÖK, H. P.; TONENCHI, L.; WETZKE, M.; BRAND, S.; LOHSE, P.; KLEIN, W.; EPPLEN, J. T.; SCHIEMANN, U.; FOLWACNY, C.; FOLWACNY, M.; MUSSAC, T.: Keine Assoziation von Polymorphismen im PPARG Gen und chronisch-entzüdlichen Darmerkrankungen, Z. Gastroenterol, **44**, (2006)

[93] N.N.: Chronisch-entzündliche Darmerkrankungen: Mesalazin wirkt erhöhtem Karzinomrisiko entgegen, Journal Onkologie, (2007)

[94] LEHMANN, J.: Para-Aminosalicylic Acid in the Treatment of Tuberculosis, The Lancet, **247**, 15-16, (1946)

[95] RENGARAJAN; J.; SASSETTI, C. M.; NARODITSCHKAYA, V.; SLOUTSKY, A.; BLOOM, B. R.; RUBIN, E. J.: The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria, Mol. Microbiol., **53**, 275-282, (2004)

[96] AMMON, H. P. T.: Arzneimittel- und Wechselwirkungen, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, **4. Auflage**, 1441-1455, (2001)

[97] LEARMONTH, D. A.: Regioselective nitration of phenolic compounds into ortho-nitrophenolic compounds using alkyl nitrates as the nitration agents, Brit. UK Pat. Appl., Pat.-Nr.: GB 2377934, (2003)

[98] MANN, J.: Timeline: Natural products in cancer chemotherapy: past, present and future, Nat. Rev. Cancer, **2**, 143-148, (2002)

[99] CUSHMAN, M.; NAGARATHNAM, D.; GOPAL, D.: Synthesis and Evaluation of Stilbene and Dihydrostilbene Derivatives as Potential Anticancer Agents that inhibit Tubulin Polymerization, J. Med. Chem.,**34**, 2579-2588, (1999)

[100] ABDEL-MAGID, A. F.; CARSON, K. G.; HARRIS, B, D.; MARYANOFF, C. A.; SHAH, R. D: Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures, J. Org. Chem., **61**, 3849-3862, (1996)

[101] BRÜCKNER, R.: Reaktionsmechanismen, Elsevier Spektrum Akademischer Verlag München, **3. Auflage**, 787-788, (2004)

[102] TIBES, R.; TRENT, J.; KURZROCK, R.: Tyrosine Kinase Inhibitors and the Dawn of Molecular Cancer Therapeutics, Annu. Rev. Pharmacol. Toxicol., **45**, 357-385, (2005)

[103] PÉREZ-SOLER, R.; CHACHOUA, A.; HAMMOND, L. A.; ROWINSKY, E. K.; HUBERMAN, M.; KARP, D.; RIGAS, J.; CLARK, G. M.; SANTABÁRBARA, P.; BONOMI, P.: Determinants of Tumor Response and Survival With Erlotinib in Patients With Non-Small-Cell Lung Cancer, J. Clinic. Oncol., **22**, 3238-3247, (2004)

[104] BRÜCKNER, R.: Reaktionsmechanismen, Elsevier Spektrum Akademischer Verlag München, **3. Auflage**, 93-94, (2004)

[105] LUMETZBERGER, A.: Potentielle VEGFR- und EGFR-Tyrosinkinase-Inhibitoren des 2-Indolinon- und des 4-Anilinochinazolin-Typs, Dissertation, Freie Universität Berlin, (2004)

[106] KNIGHT, L. A.; NICOLANTONIO, F. D.; WHITEHOUSE, P.; MERCER, S.; SHARMA, S.; GLAYSHER, S.; JOHNSON, P.; CREE, I. A.: The in vitro effect of gefitinib ('Iressa') alone

and in combination with cytotoxic chemotherapy on human solid tumors, BMC Cancer, **4**, (2004)

[107] KITCHEN, D. B.; REICH, M. F.; WISSNER, A.; TSOU, H.-R.; FLOYD, M. B.; JOHNSON, B. D.: Substituted 3-cyano Quinalines, World patent application, WO 9843960, (1998)

[108] Hennequin, L. F. A.; Ple, P.: Preparation of 4-anilinoquinazolines as antitumoragents, Int. Appl., (2002)

[109] GÜNTHER, G.: NMR-Spektroskopie, Georg Thieme Verlag, Stuttgart, 192-198, (1992)

[110] CHENG, K.; KOLAND, J. G.: Nucleotide binding by the epidermal growth factor receptor protein-tyrosine kinase, J. Biol. Chem., **271**, 311-318, (1996)

[111] FARLEY, K.; METT, H.; MCGLYNN, E.; MURRAY, B.; LYNDON, N. B.: Development of solid pahase enzyme-linked immunosorbent assays for the determination of epidermal growth factor receptor and pp60c-src tyrosine kinase activity, Anal. Biochem., **203**, 151-157, (1992)

[112] BARBACCI, E. G.; PUSTILNIK, L. R.; ROSSI, A. M.; EMERSON, E.; MILLER, P. E.; BOSCOE, B. P.; COX, E. D.; IWATA, K. K.; JANI, J. P.; PROVONCHA, K.; KATH, J. C.; LIU, Z.; MOYER, J. D.: The biological and biochemical effects of CP-654577, a selctive erbB2 kinase inhibitor, on human breast cancer cells, Cancer. Res., **63**, 4450-4459, (2003)

[113] LIU, E.; THOR, A.; HE, M.; BARCOS, M.; LJUNG, B-M., BENZ, C.: The HER2 (c-erbB-2) oncogene is frequently amplified insitu carcinomas of the breast, Oncogene, **7**, 1027-1032, (1992)

[114] SHOEMAKER, R. H.: The NCI 60 human tumour cell line anticancer drug screen, Nat. Rev. Cancer, **6**, (2006)

[115] PLOWMAN, J.; DYKES, D. J.; HOLLINGSHEAD, M.; SIMPSON-HERREN, L.; ALLEY, M. C.: Human Tumor Xenograft Models in NCI Drug Development, Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval, Humana Press, Inc. Totowa, New Jersey, 101-125, (1997)

[116] BERGEMANN, S.: Persönliche Mitteilung

[117] SCHMIDT, K.: Struktur-Wirkungsstudien an estrogen wirksamen 1,2-Diaryl-ethanderivaten sowie an antitumoraktiven Acetylenhexacarbonyl-dikobaltkomplexen, Dissertation, Freie Universität: Berlin, (2000)

[118] TAHIR, S. K.; KOVAR, P.; ROSENBERG, S. H.; NG, S. C.: Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin, BioTechniques, **29**, 156-160, (2000)

[119] WEISENBERG, R. C.; BORISY, G.G.; TAYLOR, E. W.: The colchicine-binding protein of mammalian brain and ist relation to microtubules, Biochem. **7**, 4466-4479, (1968)